News | February 08, 2022
Granules India Q3FY22 PAT at Rs 100.88 cr.
Granules India has reported consolidated financial results for the period ended December 31, 2021
Granules India has reported consolidated financial results for the period ended December 31, 2021
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
The acquisition of myPOLS Biotec complements Medix Biochemica’s leading portfolio of IVD raw materials and expands its reagent offerings for molecular diagnostics
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists
The aim is to strengthen industry-academia cooperation
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
Avra Labs is a Hyderabad based contract manufacturing and research services (CRAMs) and specialty active pharmaceutical ingredients (API) manufacturer with four facilities across the states of Telangana and Andhra Pradesh
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Subscribe To Our Newsletter & Stay Updated
